Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Ehmann

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Archives of Gynecology and Obstetrics|February 15, 2020
Sentinel lymph node mapping with fluorescent and radioactive tracers in vulvar cancer patientsSonia Prader, Andreas du Bois, Philipp Harter, et al.
Geburtshilfe Und Frauenheilkunde|September 9, 2020
Prevalence of <i>BRCA1</i> and <i>BRCA2</i> Mutations in Patients with Primary Ovarian Cancer - Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?Beyhan Ataseven, Denise Tripon, Kerstin Rhiem, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 18, 2025
Cytoreductive surgery for recurrent platinum-sensitive low-grade ovarian carcinoma: a retrospective single institution experienceMaximilian Pruss, Mareike Bommert, Sarah Ehmann, et al.
Gynecologic Oncology|December 24, 2022
Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary studySarah Ehmann, Kelly Shay, Qin Zhou, et al.
Gynecologic Oncology|April 19, 2024
Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancerSarah Ehmann, Clarissa Lam, Qin Zhou, et al.
Gynecologic Oncology|September 25, 2023
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancerWilliam A Zammarrelli, Weining Ma, Kevin Espino, et al.
Archives of Gynecology and Obstetrics|March 12, 2021
Modern day screening for Lynch syndrome in endometrial cancer: the KEM experienceNina Pauly, Thaïs Baert, Rita Schmutzler, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 15, 2025
Evaluating the risk of diaphragmatic hernia following left diaphragm resections during cytoreductive surgery for ovarian cancer: a Memorial Sloan Kettering Cancer Center Team Ovary studyRyan M Kahn, Sarah Anderson, Effi Yeoshoua, et al.
Gynecologic Oncology|July 16, 2023
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary studyTiffany Y Sia, Beryl L Manning-Geist, Sarah Ehmann, et al.
JCO Precision Oncology|October 14, 2022
Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular ClassificationWilliam A Zammarrelli, Sarah H Kim, Arnaud Da Cruz Paula, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Archives of Gynecology and Obstetrics|February 15, 2020
Sentinel lymph node mapping with fluorescent and radioactive tracers in vulvar cancer patientsSonia Prader, Andreas du Bois, Philipp Harter, et al.
Geburtshilfe Und Frauenheilkunde|September 9, 2020
Prevalence of <i>BRCA1</i> and <i>BRCA2</i> Mutations in Patients with Primary Ovarian Cancer - Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?Beyhan Ataseven, Denise Tripon, Kerstin Rhiem, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 18, 2025
Cytoreductive surgery for recurrent platinum-sensitive low-grade ovarian carcinoma: a retrospective single institution experienceMaximilian Pruss, Mareike Bommert, Sarah Ehmann, et al.
Gynecologic Oncology|December 24, 2022
Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary studySarah Ehmann, Kelly Shay, Qin Zhou, et al.
Gynecologic Oncology|April 19, 2024
Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancerSarah Ehmann, Clarissa Lam, Qin Zhou, et al.
Gynecologic Oncology|September 25, 2023
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancerWilliam A Zammarrelli, Weining Ma, Kevin Espino, et al.
Archives of Gynecology and Obstetrics|March 12, 2021
Modern day screening for Lynch syndrome in endometrial cancer: the KEM experienceNina Pauly, Thaïs Baert, Rita Schmutzler, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 15, 2025
Evaluating the risk of diaphragmatic hernia following left diaphragm resections during cytoreductive surgery for ovarian cancer: a Memorial Sloan Kettering Cancer Center Team Ovary studyRyan M Kahn, Sarah Anderson, Effi Yeoshoua, et al.
Gynecologic Oncology|July 16, 2023
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary studyTiffany Y Sia, Beryl L Manning-Geist, Sarah Ehmann, et al.
JCO Precision Oncology|October 14, 2022
Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular ClassificationWilliam A Zammarrelli, Sarah H Kim, Arnaud Da Cruz Paula, et al.
Pageof 3